Loading the section
The price of Arrowhead Pharmaceuticals, Inc. (ARWR) on October 9, 2026 is 62.67 USD, +3.18% on the day. Over 52 weeks the stock traded between 34.61 USD and 95.49 USD; the price now sits 43% of the way up that range. Over the past year the price changed by +66.23%. Market capitalization is 8.54 billion USD, rank 27 among 374 stocks of the same industry with a known capitalization.
Prices delayed by 15 minutes
Next earnings report: none scheduled in the next five weeks · Earnings calendar
Arrowhead Pharmaceuticals, Inc. trades on Nasdaq under the ticker ARWR. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks ARWR has traded between 34.61 $ and 95.49 $. As of 09 October 2026 the price stood 42.92 % of the way from the 52-week low to the high.
Over one year ARWR shares rose 66.23 %; over six months they fell 8.29 %. Volatility over 90 days is 56.55 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 13.7, above the sector median of 3.9. Price to book is 13.9, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 60.54 | 61.13 | 59.21 | 60.74 | 2M |
| 07 October 2026 | 61.63 | 62.75 | 60.78 | 61.48 | 2M |
| 06 October 2026 | 62.86 | 63.19 | 60.56 | 61.54 | 2M |
| 05 October 2026 | 64.76 | 64.76 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Arrowhead switches off individual genes in the liver and other organs — the same principle as RNA interference drugs.
The drug does not block an already-made protein but stops the cell from synthesising it. The company developed a way to deliver such molecules to a specific organ, and that is its main asset: the technology applies to a whole range of diseases rather than to one.
Its development model is not to bring everything to market itself but to license programmes to large pharmaceutical companies, receiving milestone payments and future royalties. That reduces the need for capital while limiting the share of success. Its own programmes address inherited metabolic disorders and cardiovascular risk. Risks: trial outcomes and the funding runway. The company pays no dividend.
Address:177 E COLORADO BLVD SUITE 700, PASADENA, CA, 91105, US
Arrowhead Pharmaceuticals, Inc. reported revenue of 622M $ and a net loss of 301M $ over the last four quarters. Net margin is −48.38 %. Revenue changed by +14.09 % year over year. Earnings per share are −2.26 $. Market capitalisation is 8.5B $.
ARWR has a return on equity of −49.01 %, below the sector median of −41.68 %. Return on assets is −13.27 %, above the sector median of −32.11 %. Operating margin is −35.67 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 62.22 |
| 62.35 |
| 2M |
| 02 October 2026 | 65.57 | 66.16 | 63.99 | 64.19 | 1M |
| 01 October 2026 | 65.00 | 65.76 | 64.50 | 64.79 | 2M |
| 30 September 2026 | 66.80 | 66.80 | 65.09 | 65.45 | 2M |
| 29 September 2026 | 65.46 | 66.83 | 64.57 | 66.25 | 3M |
| 28 September 2026 | 65.00 | 66.11 | 63.99 | 65.46 | 2M |
| 25 September 2026 | 66.50 | 67.44 | 65.40 | 65.92 | 2M |
| 24 September 2026 | 67.00 | 67.45 | 65.46 | 66.07 | 2M |
| 23 September 2026 | 72.16 | 72.49 | 66.27 | 66.96 | 3M |
| 22 September 2026 | 68.85 | 72.37 | 68.08 | 71.86 | 3M |
| 21 September 2026 | 67.46 | 69.26 | 66.06 | 68.79 | 2M |
| 18 September 2026 | 67.83 | 68.05 | 66.36 | 66.48 | 4M |
| 17 September 2026 | 68.91 | 68.91 | 67.00 | 67.74 | 3M |
| 16 September 2026 | 70.41 | 71.93 | 64.50 | 65.79 | 5M |
| 15 September 2026 | 82.89 | 83.55 | 70.61 | 70.67 | 4M |
| 14 September 2026 | 82.98 | 83.27 | 79.93 | 80.67 | 1M |
| 11 September 2026 | 83.75 | 85.98 | 82.36 | 82.85 | 1M |